… and functions of SHP2, and briefly review the development of SHP2 inhibitors. Importantly, …
to overcome drug resistance and synergistic tumor immunotherapy using SHP2 inhibitors. We …

… of SHP2 inhibitors in 3D growth environments as compared to traditional 2D culture. In
vivo, SHP2 inhibition … with FGFR-targeted kinase inhibitors. Overall, we posit that combined …

… Our results suggest that SHP2 inhibition could provide a general strategy for preventing
MEKi resistance in a wide range of malignancies and might also have single-agent efficacy …

… with agents (eg, MEK, KRAS, RTK, and PD-1/PD-L1 inhibitors) may produce less drug
resistance in patients compared with a single agent. (135,174) Though the importance of …

… However, the development of novel SHP2 inhibitors is necessary to improve the therapeutic
strategies for hematological malignancies and tackle drug resistance and disease relapse. …

… However, patients eventually develop resistance to drugs. … of Shp2 in drug resistance has
been partially revealed, Shp2 … inhibitor of Shp2 may be used in combination therapy drugs. …

… SHP2 inhibitor by regulation the co-interaction of SHP2, … SHP2 inhibitors may be used
as new therapeutic drugs for CML patients bearing BCR-ABL T315I mutation. In BLU-667-resistant …

… Unfortunately, these patients develop drug resistance after treatment, due to acquired …
prevent EGFR inhibition, we sought to determine whether small molecule SHP2 inhibitors could be …

… ALK and SHP2 inhibition may provide a broad-reaching therapeutic strategy for overcoming
or preventing heterogeneous ALK-independent mechanisms of acquired drug resistance in …

… This paper reviews allosteric inhibitors of SHP2 published in patents … drug resistance is
still a major challenge. The combination of SHP2 allosteric inhibitors and immunotherapy drugs …